

ALDESLEUKIN

SYNONYMS	Human recombinant interleukin-2
BRAND NAME	PROLEUKIN
DRUG CLASS	Non-cytotoxic antineoplastic, interleukin
AVAILABILITY	<p>Vial contains 22 million international units (1.3 mg) of aldesleukin. Also contains mannitol, sodium dodecyl sulfate, sodium dihydrogen phosphate dihydrate and disodium hydrogen phosphate dihydrate.¹</p> <p>Product available may be described as containing 18 million international units/mL after reconstitution.</p> <p>Available via the Special Access Scheme.</p> <div style="border: 2px solid red; padding: 5px;"><p>The occupational hazard of intermittent low dose exposure to aldesleukin is not known. Wear a mask and gloves when preparing the infusion solution to minimise exposure. Aldesleukin is not a cytotoxic.</p></div>
pH	7.2–7.8 ¹
PREPARATION	<p>Reconstitute the vial with 1.2 mL of water for injections. Inject the water down the side of the vial and swirl gently. Do not shake.¹</p> <p>The concentration is 18 million international units (1.1 mg) per mL. The solution is clear and colourless to slightly yellow.¹</p> <p>Dilute the dose in 50 mL of glucose 5%.¹</p> <p>If the dose is 1.5 mg or less, dilute in a smaller volume of glucose 5%. The final concentration should be 30–70 microgram/mL.¹</p> <p>If concentrations of less than 30 microgram/mL are required, add albumin 0.1% to the glucose 5% to prevent variability in stability and bioactivity.²</p>
STABILITY	<p>Vial: store at 2 to 8 °C. Do not freeze. Protect from light.¹</p> <p>When prepared by pharmacy under aseptic conditions:</p> <p>Reconstituted solution: stable for 48 hours below 25 °C or at 2 to 8 °C.¹ Do not freeze.¹</p> <p>Infusion solution: stable for 48 hours below 25 °C or at 2 to 8 °C. Do not freeze. Use within 48 hours of reconstitution.¹</p>
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	Not recommended
IV injection	Not recommended
IV infusion	Infuse over 15 minutes. ¹ Do not use an inline filter. ¹
COMPATIBILITY	Glucose 5% ¹
INCOMPATIBILITY	Sodium chloride 0.9% ¹ , bacteriostatic water for injections ¹
SPECIAL NOTES	<p>Aldesleukin is moderately emetogenic. Premedication with a 5HT₃ antagonist may be required.³ Check your local guidelines.</p> <p>Aldesleukin has been associated with capillary leak syndrome which is characterised by a loss of vascular tone and extravasation of plasma proteins into the extravascular space. Monitor blood pressure.¹</p> <p>Withhold treatment if the patient develops moderate to severe lethargy or sleepiness.¹</p> <p>Dexamethasone reduces both the toxicity and the therapeutic effect of aldesleukin. Reserve the use of dexamethasone for life-threatening toxicities.¹</p>

REFERENCES

1. Proleukin. US Prescribing information. San Diego, CA: Prometheus Laboratories. Updated May 2019. Available from www.dailymed.nlm.nih.gov. Accessed 01/11/2019.
2. McEvoy GK, editor. Handbook on injectable drugs. 20th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2018.
3. Clinical resource: Prevention of antineoplastic induced nausea and vomiting [v4 January 2019]. eviQ [internet]. Sydney: Cancer Institute NSW. Available from www.eviq.org.au. Accessed 10/10/2019.